Quanterix Corporation filings document the regulatory record of a life sciences company built around ultra-sensitive biomarker instruments, consumables, assay services, and clinical laboratory testing. Its Form 8-K disclosures include operating and financial results, material-event reports, clinical or regulatory disclosures, capital-structure items, and leadership or board changes.
Proxy materials for QTRX describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, equity incentive plan approvals, and governance provisions. The filing record also covers shareholder voting results and charter-related governance matters, providing formal disclosure of the company’s board structure, compensation framework, ownership voting mechanics, and public-company controls.
Portolan Capital Management, LLC and its manager George McCabe report beneficial ownership of 3,633,622 shares of Quanterix Corp common stock, representing 9.36% of the class, as disclosed on a Schedule 13G (Amendment No. 3). The filing shows sole voting and sole dispositive power over these shares and indicates Portolan acts in its capacity as a registered investment adviser while Mr. McCabe is identified as the manager with indirect interest.
The statement includes a certification that the securities were not acquired to change or influence control of the issuer, consistent with a passive 13G filing. No shared voting or dispositive powers are reported and no other holders are identified in this filing.
Quanterix Corporation is asking stockholders to vote at a virtual annual meeting at 9:00 a.m. ET on September 23, 2025. Holders of record as of July 31, 2025 may vote on six proposals, including the election of three directors (Myla Lai-Goldman, Masoud Toloue and David Walt), an advisory say-on-pay vote, ratification of KPMG LLP as auditor, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaws amendments.
The company completed the acquisition of Akoya Biosciences on July 8, 2025, which led to two Akoya directors joining Quanterix and two predecessors resigning. A Cooperation Agreement with activist holder Kent Lake was reached on August 4, 2025, which includes appointing one independent director by December 1, 2025 and seeking Board declassification. The Board recommends voting in favor of all proposals.
Quanterix Corporation (QTRX) filed Post-Effective Amendment No. 3 on Form S-8 to its previously declared-effective Form S-4, completing the technical step needed to register shares that will be issued under equity awards assumed from Akoya Biosciences following the recently closed merger.
- Shares registered: 253,181 shares of Quanterix common stock, representing the maximum issuable upon vesting of outstanding Akoya restricted stock units ("Rollover RSUs").
- Merger exchange ratio: each Akoya share converted at closing into 0.1470 Quanterix share plus $0.37 cash.
- Total shares previously registered: 8,357,169 on the original Form S-4, covering stock consideration to Akoya shareholders and all equity awards; today’s filing carves out only the RSU component.
- Fees: all SEC filing fees were paid with the original Form S-4; no additional fees are due.
- Plan coverage: the amendment relates to the Akoya Biosciences 2015 & 2021 Equity Incentive Plans, now assumed by Quanterix.
- Rule 416(a) applicability: automatic coverage for share increases from stock splits, dividends, or similar corporate actions.
Part II of the filing reiterates standard incorporation by reference of recent Quanterix periodic reports, describes Delaware law-based indemnification provisions, and lists exhibits, including opinions from Covington & Burling LLP and auditor consents. The document is strictly administrative—no new financial results, guidance, or strategic changes are disclosed; its primary purpose is to ensure that shares underlying assumed Akoya equity awards are properly registered for issuance post-merger.